All In Biotech

Drug Trial Radar · NCT02950051

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 926 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

926

Actual

Start

Dec 13, 2016

Primary completion

Feb 29, 2024

Study completion Feb 29, 2024

Sponsor

Lead sponsor
German CLL Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Janssen-Cilag Ltd.; Hoffmann-La Roche; AbbVie; Stichting Hemato-Oncologie voor Volwassenen Nederland; Nordic CLL Study Group; Swiss Cancer Institute; Cancer Trials Ireland; Israeli CLL Study Group
First posted
Oct 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by combinations of targeted drugs (Venetoclax, Ibrutinib) with anti-CD20-antibodies (Rituximab, Obinutuzumab), which may induce extremely long lasting remissions.

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • FludarabineDrug

    Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d

  • CyclophosphamideDrug

    Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d

  • RituximabBiological

    Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d

  • BendamustineDrug

    Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d

  • VenetoclaxDrug

    Venetoclax p.o. (ramp-up: dose escalation until final dose is reached) cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d

  • ObinutuzumabBiological

    Obinutuzumab i.v. cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d cycles 2-6: 1000 mg, d1, q28d

  • IbrutinibDrug

    Ibrutinib p.o. cycles 1-12: 420 mg, d1-28, q28d cycles 13-36: 420 mg, d1-28, q28d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)Time frame: Month 15
  2. Progression free survival (PFS)Time frame: anticipated for January 2023 (after 213 events occured and 73 months after the first patient has been randomized

Locations

161 sites in 10 countries. Site status is shown where the registry gives one.

  • Medizinische Universitaet Wien

    Vienna, Austria

  • Hanusch Hospital

    Vienna, Austria

  • Wilhelminenspital

    Vienna, Austria

  • ZNA Stuivenberg

    Antwerp, Belgium

  • Algemeen Ziekenhuis St. Jan

    Bruges, Belgium

  • Jan Yperman Ziekenhuis

    Ieper, Belgium

  • UZ Gasthuisberg

    Leuven, Belgium

  • AZ Delta

    Roeselare, Belgium

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Rigshospitalet/Copenhagen

    Copenhagen, Denmark

  • Sydvestjysk Sygehus Esbjerg

    Esbjerg, Denmark

  • University Hospital Herlev

    Herlev, Denmark

  • Regionshospitalet Holstebro

    Holstebro, Denmark

  • Odense Universitets Hospital

    Odense, Denmark

  • Sjællands Universitetshospital

    Roskilde, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Helsinki University Hospital

    Helsinki, Finland

  • Jyväskylä Central Hospital

    Jyväskylä, Finland

  • Oulu University Hospital

    Oulu, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital

    Turku, Finland

  • Gesundheitszentrum Klinikum St Marien

    Amberg, Germany

  • Onkologische Schwerpunktpraxis Kurfürstendamm

    Berlin, Germany

  • Helios-Klinikum Berlin

    Berlin, Germany

  • ZAHO Bonn

    Bonn, Germany

  • Ev. Diakonie-Krankenhaus gemeinnuetzige GmbH

    Bremen, Germany

  • University Hospital of Cologne

    Cologne, Germany

  • St. -Johannes-Hospital Dortmund

    Dortmund, Germany

  • Gefos Dortmund mbH

    Dortmund, Germany

  • BAG Dresden

    Dresden, Germany

  • Universitaetsklinik Carl Gustav Carus

    Dresden, Germany

  • Marien Hospital Düsseldorf GmbH

    Düsseldorf, Germany

  • St. Georg Klinikum Eisenach GmbH

    Eisenach, Germany

  • Helios Klinikum Erfurt

    Erfurt, Germany

  • St. Antonius-Hospital

    Eschweiler, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

  • Centrum fuer Haematologie und Onkologie Bethanien

    Frankfurt, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • MVZ Onkologische Kooperation Harz, Drs. Tessen/Hoyer/Zahn

    Goslar, Germany

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.